Austedo

Teva Pharmaceutical Industries has unveiled a strategic plan targeting up to $7 billion in annual innovative drug revenue by 2030, aiming to reduce reliance on generics and boost profitability.

A decade after a severe financial crisis, Teva Pharmaceutical Industries is completing its turnaround under CEO Richard Francis, transitioning to common stock on the NYSE and advancing its innovative biopharma pipeline.